BRIEF-Cosmos Holdings says signed new LoI to acquire outstanding shares of CC Pharma GmbH
* Cosmos Holdings Inc says signed a new letter of intent to acquire outstanding shares of CC Pharma GmbH
March 21 Neurocrine Biosciences Inc
* Positive results from Kinect 3 phase iii study of Ingrezza (valbenazine) for treatment of tardive dyskinesia (td)
* Has submitted NDA to FDA for ingrezza and has been granted priority review with a pdufa action date of April 11, 2017
* Says Ingrezza was found to be generally well tolerated with adverse events consistent with those of prior studies Source text for Eikon: Further company coverage:
JOHANNESBURG, June 23 The South African parliament is planning to challenge in court an anti-graft watchdog's recommendation of constitutional changes to the mandate of the central bank, it said on Friday, highlighting worsening divisions between state institutions.